Europe - Euronext Milan - BIT:1EW - US28176E1082 - Common Stock
The current stock price of 1EW.MI is 73.47 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 2M6.DE | MEDTRONIC PLC | 17.67 | 109.18B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 19.46 | 52.46B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 17.17 | 24.47B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 17.18 | 24.49B | ||
| BIM.PA | BIOMERIEUX | 29.25 | 13.36B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 150 | 4.51B | ||
| DIA.MI | DIASORIN SPA | 21.93 | 4.06B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 25.63 | 3.69B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 11.66 | 1.41B | ||
| ELN.MI | EL.EN. SPA | 22.86 | 1.18B | ||
| DRW8.DE | DRAEGERWERK AG | 9.55 | 1.16B | ||
| EUZ.DE | ECKERT & ZIEGLER SE | 25.11 | 1.04B |
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
EDWARDS LIFESCIENCES CORP
One Edwards Way
Irvine CALIFORNIA US
Employees: 15800
Phone: 19492502500
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. The company is headquartered in Irvine, California and currently employs 15,800 full-time employees. The company went IPO on 2000-03-27. The firm partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. The company provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. The company is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
The current stock price of 1EW.MI is 73.47 EUR. The price increased by 10.51% in the last trading session.
1EW.MI does not pay a dividend.
1EW.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
EDWARDS LIFESCIENCES CORP (1EW.MI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
The PE ratio for EDWARDS LIFESCIENCES CORP (1EW.MI) is 32.95. This is based on the reported non-GAAP earnings per share of 2.23 and the current share price of 73.47 EUR.
EDWARDS LIFESCIENCES CORP (1EW.MI) has a market capitalization of 42.63B EUR. This makes 1EW.MI a Large Cap stock.
ChartMill assigns a technical rating of 2 / 10 to 1EW.MI.
ChartMill assigns a fundamental rating of 7 / 10 to 1EW.MI. Both the health and profitability get an excellent rating, making 1EW.MI a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months 1EW.MI reported a non-GAAP Earnings per Share(EPS) of 2.23. The EPS decreased by -3.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 23.25% | ||
| ROA | 10.31% | ||
| ROE | 13.4% | ||
| Debt/Equity | 0.06 |
43 analysts have analysed 1EW.MI and the average price target is 81.34 EUR. This implies a price increase of 10.72% is expected in the next year compared to the current price of 73.47.
For the next year, analysts expect an EPS growth of 0.42% and a revenue growth 4.33% for 1EW.MI